IDO1 and hepatocellular carcinoma: Moreover, in this study treatment with a LIN28 inhibitor, C1632, significantly augmented the tumor-killing activity of the GPC3-CAR T cells against hepatocellular carcinoma cell (HCC) lines in vitro and in vivo through inhibition of PD-L1 and IDO in the tumor.